Is Semax FDA approved? What researchers need to know in 2026

Last updated 2026-07-24

What is Semax's FDA approval status?

Semax has zero FDA approval. The peptide does not appear in the FDA's approved drug products database (Drugs@FDA) under any name, formulation, or indication ^[1]. It is not a recognized drug for any human use in the United States. The FDA maintains two lists of bulk substances permitted for compounding: the 503A list (for traditional compounding pharmacies) under 21 CFR 216.23 ^[2] and the 503B list (for outsourcing facilities) under 21 CFR 216.24 ^[3]. Semax appears on neither. A pharmacy cannot legally compound Semax for a patient under the exemptions in 21 U.S.C. 353a without breaking federal law ^[4]. Semax also does not appear on the FDA's current list of nominated bulk substances under consideration for addition to the 503A list ^[5]. No sponsor has filed an investigational new drug application (IND) or new drug application (NDA) for Semax in the United States. Where Semax is available in the US, it is supplied as a research product or through gray-market channels. Its sale for human consumption is not authorized by federal drug law.

Where does Semax have regulatory approval?

Semax holds regulatory approval in Russia, where it was developed in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is registered as a pharmaceutical drug for the treatment of acute ischemic stroke, optic nerve diseases, and cognitive impairments. Russian clinicians have prescribed it for more than three decades. The peptide also has approval in Ukraine, Kazakhstan, and Belarus. It is not approved in any European Union member state, Canada, Australia, or Japan. The approval pathway in Russia differs from the FDA's standards. Russian clinical trials in the 1980s and 1990s often lacked the double-blind, placebo-controlled design the FDA requires. A 2018 study published in Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova reported efficacy in ischemic stroke patients at different stages ^[6], but the trial design and endpoint definitions do not meet current Western regulatory standards for registration trials.

What is Semax's legal status under US drug law?

Under 21 CFR 201.128, the FDA considers any substance offered for medical use to have "intended uses" that trigger drug regulation ^[7]. Semax marketed with cognitive, neuroprotective, or therapeutic claims is an unapproved drug under the Federal Food, Drug, and Cosmetic Act. Semax is not a controlled substance under the Controlled Substances Act. It is not scheduled by the DEA. Possession is not illegal, but its sale for human use violates FDA drug approval requirements. Compounding pharmacies sometimes offer Semax as a "research peptide" or "not for human consumption" product to avoid the 503A and 503B restrictions ^[2][3]. These disclaimers do not insulate the seller from enforcement. The FDA has issued warning letters to peptide vendors for marketing unapproved drugs with therapeutic claims. Some US patients obtain Semax from international suppliers based in Russia or Eastern Europe. Importing unapproved drugs for personal use occupies a gray area. The FDA generally does not prosecute individuals importing small quantities for personal use, but Customs and Border Protection may seize packages.

What evidence supports Semax's use?

Semax has a large Russian-language literature and a smaller body of English-language research. The evidence is real but unevenly distributed. Most trials are animal models or small human studies without Western-style placebo controls. A 2014 genome-wide transcriptional analysis published in BMC Genomics found that Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia ^[8]. A 2017 study in Molecular Genetics and Genomics reported that Semax regulates expression of immune response genes during ischemic brain injury in rats ^[9]. A 2021 study in the International Journal of Molecular Sciences confirmed protective effects at the protein expression level in a rat cerebral ischemia-reperfusion model ^[10]. Animal models show consistent neuroprotective effects. A 2020 study in Genes documented transcriptome-level changes following cerebral ischemia-reperfusion in rats treated with the ACTH(4-7)PGP peptide (Semax) ^[11]. A 2022 study in Genes examined the modulation of inflammatory and neurosignaling genetic response following cerebral ischemia-reperfusion ^[12]. A 2024 study in Biomedicines found that ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke ^[13]. Human studies are fewer and less rigorous by current standards. A 2010 study in Cellular and Molecular Neurobiology reported that Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia ^[14]. A 2018 study in the Bulletin of Experimental Biology and Medicine used fMRI to measure effects on the default mode network of the brain ^[15]. The sample size was small and the study lacked a control group. A 2025 study in the British Journal of Pharmacology reported that Semax targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice ^[16]. The mechanism was specific and the effect was measurable, but the study was in mice and the pathway has not been confirmed in humans. No Semax study has been published in the New England Journal of Medicine, JAMA, Lancet, or any other top-tier general medical journal. No Western institution has run a multi-site, placebo-controlled trial. The evidence is enough to say Semax does something in animal models. It is not enough to say it works in humans at the standard required for FDA approval.

How does Semax compare to FDA-approved nootropics?

The FDA has approved exactly zero drugs for the specific indication of cognitive enhancement in healthy people. What are commonly called "nootropics" in the United States are either approved for other indications (modafinil for narcolepsy, methylphenidate for ADHD) or sold as dietary supplements (caffeine, L-theanine, bacopa). Semax is structurally an analog of ACTH(4-10), a fragment of adrenocorticotropic hormone. A 2005 study in Neurochemical Research reported that Semax activates dopaminergic and serotonergic brain systems in rodents ^[17]. A 2006 study in the Journal of Neurochemistry found that Semax binds specifically and increases levels of brain-derived neurotrophic factor (BDNF) protein in rat basal forebrain ^[18]. The same neurotrophic pathway is targeted by FDA-approved drugs for depression and Alzheimer's, but Semax is not one of them. A 2020 study in Doklady Biological Sciences used a functional connectomic approach to compare Selank and Semax effects ^[19]. Both peptides are Russian-origin regulatory peptides. Neither has FDA approval. Both have similar evidence profiles: strong Russian institutional backing, animal models, small human trials, no Western replication. The closest FDA-approved comparator is probably intranasal insulin, which has been studied for Alzheimer's disease in US trials but is not approved for that indication. Like Semax, intranasal insulin bypasses the blood-brain barrier and has a plausible mechanism. Unlike Semax, it has been tested in NIH-funded trials at US universities.

What are the risks of using an unapproved peptide?

Using Semax in the United States carries three categories of risk: product quality, legal exposure, and unknown safety profile. Product quality is the most immediate concern. Without FDA oversight, there is no guarantee that a vial labeled "Semax" contains Semax at the stated dose. A 2018 study in Current Pharmaceutical Design discussed pharmacological aspects of neuro-immune interactions and noted the difficulty of ensuring peptide stability and purity outside regulated supply chains ^[20]. Peptides degrade quickly. Storage conditions matter. A compounding pharmacy in the US that offers Semax is operating outside its legal authority ^[2][3], and it may also be cutting corners on sterility testing or peptide sourcing. Legal exposure is modest for individual users. The FDA does not prosecute people who buy peptides for personal use, but it can seize shipments. A US physician who prescribes Semax could face disciplinary action from a state medical board. A pharmacy that compounds Semax could receive a warning letter or consent decree from the FDA. The unknown safety profile is harder to quantify. Semax has been used in Russia for 30 years without reports of widespread harm. A 2021 study in Neuropeptides found that Semax attenuates behavioral and neurochemical alterations following early-life fluvoxamine exposure in white rats ^[21]. A 2023 study in Chemical Biology & Drug Design examined synthetic corticotropins and the GABA-receptor system and found both direct and delayed effects ^[22]. These suggest Semax interacts with multiple neurotransmitter systems. We don't know what happens with long-term use in humans, at what dose toxicity appears, or how it interacts with common medications. A 2008 study in CNS Spectrums explored the therapeutic possibility of Semax for depression ^[23]. The title is aspirational. The study did not establish efficacy or safety in a controlled trial.

Can I get Semax through a compounding pharmacy?

Legally, no. Semax does not appear on the 503A or 503B bulk substance lists ^[2][3], so a US compounding pharmacy cannot lawfully prepare it for a patient. The 503A exemption requires that the bulk substance be on the FDA's approved list or be a component of an FDA-approved drug. Semax is neither ^[4]. In practice, some compounding pharmacies offer Semax. They label it "for research purposes" or "not for human consumption." These disclaimers do not change the law. The FDA determines intended use by examining the totality of circumstances, including marketing materials, customer base, and dosing instructions ^[7]. A nasal spray bottle with a patient's name on it is hard to characterize as anything other than human use. [Semax Labs](/) works with licensed compounding pharmacies that prepare Semax nasal spray under provider oversight. The legal status is unchanged, the product is not FDA-approved, and the pharmacy is operating outside the 503A and 503B safe harbors. Patients considering this route should understand that they are using an unapproved drug. The provider review is a quality check, not a substitute for FDA approval. Some patients prefer to order Semax powder or pre-mixed nasal sprays from international suppliers. This avoids the awkward pretense that a US pharmacy can legally compound it, but it introduces new risks. Customs may seize the package. The supplier may send a mislabeled or contaminated product. There is no recourse if something goes wrong. For guidance on sourcing, see where to buy Semax on r/nootropics.

What would it take for Semax to get FDA approval?

Semax would need a sponsor willing to fund a multi-phase clinical development program. That means a Phase 1 safety trial in healthy volunteers, a Phase 2 dose-finding trial in patients with the target condition, and at least one Phase 3 randomized, double-blind, placebo-controlled trial large enough to detect a clinically meaningful effect. The FDA's approval standard is "substantial evidence" of effectiveness, which generally requires two adequate and well-controlled studies ^[4]. For a neuroprotective indication like stroke, the FDA would want to see reduction in disability scores or mortality at 90 days. For a cognitive indication, the FDA would want to see improvement on a validated cognitive battery that persists over months. A peptide faces additional hurdles. Peptides are expensive to manufacture under good manufacturing practice (GMP) standards. They require cold storage. They degrade in the gastrointestinal tract, so oral formulations are difficult. Semax is administered intranasally, which simplifies delivery but introduces questions about nasal irritation and long-term mucosal safety. No pharmaceutical company has taken Semax into a US clinical trial. The peptide is off-patent, so the financial incentive is limited. A generic drug company could theoretically file an abbreviated new drug application (ANDA), but an ANDA requires a reference listed drug, and there is none for Semax. The most realistic path is a small biotech licensing the Russian data, running a Phase 2 trial in stroke or traumatic brain injury, and hoping for breakthrough therapy designation or orphan drug status to speed review. That has not happened.

How should I think about Russian vs. US regulatory standards?

Russian regulatory approval is not the same as FDA approval, but it is not meaningless either. The Russian Ministry of Health reviews clinical trial data and pharmacovigilance reports. The standards differ from the FDA's, particularly for trials conducted before 2000, but they exist. A 2026 review in Frontiers in Aging discussed therapeutic peptides in gerontology and noted the gap between regional regulatory approval and global acceptance ^[24]. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons examined therapeutic peptides in orthopedics and called out the challenges of translating preclinical promise into FDA-approved products ^[25]. The core difference is replication. FDA approval requires that efficacy be demonstrated in at least two well-controlled trials, usually conducted at multiple sites, with prespecified endpoints and independent data monitoring. Russian approval in the 1980s and 1990s often relied on a single trial at a single institution. The published data are real, but they are not independently verified. A 2025 review in Neuropeptides examined the modulation of neuropathological pathways by bioactive peptides and noted the difficulty of assessing evidence quality when most studies originate from a single country ^[26]. A 2025 study in Acta Naturae explored the potential of Semax and its derivative for correcting pathological impairments in an animal model of Alzheimer's disease ^[27]. The animal work is strong. The human work is thin. For a researcher weighing the evidence, the question is: do you trust the Russian trials enough to use Semax yourself or recommend it to others? Reasonable people disagree. The trials are not fabricated, but they would not pass peer review at JAMA today. If you want a detailed look at what the evidence actually shows, start with the main Semax overview.

What about Semax derivatives like N-acetyl Semax amidate?

N-acetyl Semax amidate (NA-Semax) is a modified version of Semax with an acetyl group added to increase blood-brain barrier penetration and half-life. It is even less studied than Semax and has no regulatory approval anywhere. A 2016 study in the Journal of Inorganic Biochemistry examined the influence of N-terminus acetylation of Semax on copper(II) and zinc(II) coordination and biological properties ^[28]. The acetylation changes how Semax binds metal ions, which could affect its neuroprotective activity. A 2022 study in ACS Chemical Neuroscience found that Semax affects copper-induced Aβ aggregation and amyloid formation in artificial membrane models ^[29]. The NA-Semax variant was not directly tested, but the findings suggest that structural changes to the peptide alter its mechanism. NA-Semax is sometimes marketed as "stronger" or "longer-lasting" than Semax. The claims are plausible based on pharmacokinetics, but they are not backed by human trials. There is no published dose-response curve for NA-Semax, no safety data beyond anecdote, and no peer-reviewed comparison to standard Semax in humans. If you are trying to choose between Semax and NA-Semax, see Semax vs N-acetyl Semax amidate for a detailed breakdown. The short version: Semax has 30 years of clinical use in Russia. NA-Semax has none. Neither has FDA approval, but one has a real-world track record and the other does not.

Where can I learn more about dosing and safety?

Dosing information for Semax is drawn entirely from Russian clinical practice and animal studies. The typical intranasal dose in Russian trials is 0.3 to 3 mg per day, divided into two to three administrations. Some studies use higher doses for acute stroke. Some use lower doses for cognitive effects in healthy volunteers. There is no FDA-approved dosing guideline ^[1]. For a detailed look at dosing ranges, start with how many mg of Semax a day. For administration methods, see Semax injection, though intranasal is far more common. Safety data come from the same Russian sources. A 2010 study in Rossiiskii Fiziologicheskii Zhurnal examined nootropic and analgesic effects of Semax following different routes of administration ^[30]. The routes included intranasal, subcutaneous, and intraperitoneal in rats. The study found that route of administration affects bioavailability and effect size, but it did not report serious adverse events. No systematic review has pooled safety data from all published Semax trials. No pharmacovigilance database tracks adverse events in the US. If you are considering Semax, read Semax side effects for what is known about tolerability. The honest summary: short-term use appears safe in Russian clinical experience, but we lack long-term data and we lack data in populations outside Russia.

Frequently asked questions

Is Semax legal to buy in the United States?

Semax is not a controlled substance, so possession is not illegal. However, selling it for human use is illegal because it is an unapproved drug under the Federal Food, Drug, and Cosmetic Act. The FDA does not typically prosecute individuals who buy peptides for personal use, but it can seize shipments and issue warning letters to sellers.

Can a doctor prescribe Semax?

A doctor can write a prescription for anything, but a pharmacy cannot legally fill a prescription for Semax because it does not appear on the FDA's 503A or 503B compounding lists. A doctor who prescribes Semax risks disciplinary action from a state medical board for prescribing an unapproved drug off-label.

Has Semax been tested in clinical trials?

Yes. Semax has been tested in dozens of clinical trials in Russia, Ukraine, and other former Soviet states since the 1980s. Most trials are small, open-label, and published in Russian-language journals. No large, placebo-controlled trials have been conducted at Western institutions, and no results have been published in top-tier international medical journals.

Why hasn't Semax been approved by the FDA?

No pharmaceutical company has filed an investigational new drug application or new drug application for Semax with the FDA. The peptide is off-patent, so the financial incentive to fund the required Phase 1, 2, and 3 trials is limited. Without a sponsor willing to invest tens of millions of dollars, FDA approval will not happen.

Is Semax approved in Europe?

No. Semax is not approved by the European Medicines Agency (EMA) or by any individual EU member state. It is approved only in Russia, Ukraine, Kazakhstan, and Belarus.

What is the difference between Semax and Selank?

Semax is an analog of ACTH(4-10) with neuroprotective and cognitive effects. Selank is an analog of tuftsin with anxiolytic and immune-modulating effects. Both were developed in Russia, both lack FDA approval, and both have similar evidence profiles: strong preclinical data, modest human data, no Western replication. A 2020 study used a functional connectomic approach to compare their effects.

Can I import Semax from Russia?

Importing Semax for personal use occupies a legal gray area. The FDA generally does not prosecute individuals importing small quantities of unapproved drugs for personal use, but US Customs and Border Protection may seize packages. There is no legal recourse if the product is confiscated or if it arrives contaminated or mislabeled.

What is the typical dose of Semax used in Russian trials?

Russian clinical trials typically use 0.3 to 3 mg per day, administered intranasally in two to three divided doses. Higher doses (up to 12 mg per day) have been used in acute stroke trials. Lower doses (0.5 to 1 mg per day) have been used in healthy volunteers for cognitive effects.

Are there any serious side effects reported with Semax?

Published Russian trials report few serious adverse events. The most common side effects are mild nasal irritation and transient headache. No systematic safety review has pooled data from all trials, and no long-term safety data (beyond a few months) exist. There is no pharmacovigilance system tracking Semax adverse events in the US.

How long has Semax been used clinically?

Semax has been used in Russian clinical practice since the 1980s. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and registered as a pharmaceutical drug in Russia for stroke, optic nerve disease, and cognitive impairment. Exact patient counts are not publicly available.

Is Semax the same as ACTH?

No. Semax is a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH), specifically ACTH(4-10), with added amino acids (Pro-Gly-Pro) to increase stability. It does not have the full hormonal activity of ACTH and does not stimulate cortisol release in the same way.

What is the best way to get Semax in the US?

There is no fully legal way to obtain Semax for human use in the US. Some people order from international suppliers and accept the risk of seizure and product quality issues. Others work with compounding pharmacies that offer Semax under provider review, understanding that the pharmacy is operating outside the 503A and 503B safe harbors.

Does Semax show up on drug tests?

Standard drug tests do not screen for peptides. Semax would not show up on a urine, blood, or saliva test for common drugs of abuse or performance-enhancing drugs. However, specialized peptide testing (used in some professional sports) could detect Semax if specifically included in the test panel.

Can I use Semax if I am pregnant or breastfeeding?

There are no safety data on Semax use during pregnancy or breastfeeding. Russian package inserts list pregnancy as a contraindication. If you are pregnant, breastfeeding, or planning to become pregnant, do not use Semax. The risk to the fetus or infant is unknown.

Sources

1. FDA Drugs@FDA database: Semax does not appear in the FDA's approved drug products database under any name, formulation, or indication.
2. 21 CFR 216.23, 503A Bulks List: Semax does not appear on the FDA's 503A bulk substance list for traditional compounding pharmacies.
3. 21 CFR 216.24, 503B Bulks List: Semax does not appear on the FDA's 503B bulk substance list for outsourcing facilities.
4. 21 U.S.C. 353a, pharmacy compounding statute: A pharmacy cannot legally compound Semax for a patient under the exemptions in 21 U.S.C. 353a without breaking federal law.
5. FDA, bulk drug substances nominated for use in compounding: Semax does not appear on the FDA's current list of nominated bulk substances under consideration for addition to the 503A list.
6. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018 (PMID 29798983): A 2018 study reported efficacy of Semax in ischemic stroke patients at different stages, but the trial design does not meet current Western regulatory standards.
7. 21 CFR 201.128, meaning of intended uses: Under 21 CFR 201.128, the FDA considers any substance offered for medical use to have intended uses that trigger drug regulation.
8. BMC Genomics, 2014 (PMID 24661604): A 2014 genome-wide transcriptional analysis found that Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia.
9. Molecular Genetics and Genomics, 2017 (PMID 28255762): A 2017 study reported that Semax regulates expression of immune response genes during ischemic brain injury in rats.
10. International Journal of Molecular Sciences, 2021 (PMID 34201112): A 2021 study confirmed protective effects of Semax at the protein expression level in a rat cerebral ischemia-reperfusion model.
11. Genes, 2020 (PMID 32580520): A 2020 study documented transcriptome-level changes following cerebral ischemia-reperfusion in rats treated with Semax.
12. Genes, 2022 (PMID 36553646): A 2022 study examined the modulation of inflammatory and neurosignaling genetic response following cerebral ischemia-reperfusion.
13. Biomedicines, 2024 (PMID 39767736): A 2024 study found that ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke.
14. Cellular and Molecular Neurobiology, 2010 (PMID 19633950): A 2010 study reported that Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.
15. Bulletin of Experimental Biology and Medicine, 2018 (PMID 30225715): A 2018 study used fMRI to measure effects of Semax on the default mode network of the brain.
16. British Journal of Pharmacology, 2025 (PMID 40692165): A 2025 study reported that Semax targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
17. Neurochemical Research, 2005 (PMID 16362768): A 2005 study reported that Semax activates dopaminergic and serotonergic brain systems in rodents.
18. Journal of Neurochemistry, 2006 (PMID 16635254): A 2006 study found that Semax binds specifically and increases levels of brain-derived neurotrophic factor (BDNF) protein in rat basal forebrain.
19. Doklady Biological Sciences, 2020 (PMID 32342318): A 2020 study used a functional connectomic approach to compare Selank and Semax effects.
20. Current Pharmaceutical Design, 2018 (PMID 28875850): A 2018 study discussed pharmacological aspects of neuro-immune interactions and noted the difficulty of ensuring peptide stability and purity outside regulated supply chains.
21. Neuropeptides, 2021 (PMID 33418449): A 2021 study found that Semax attenuates behavioral and neurochemical alterations following early-life fluvoxamine exposure in white rats.
22. Chemical Biology & Drug Design, 2023 (PMID 36828803): A 2023 study examined synthetic corticotropins and the GABA-receptor system and found both direct and delayed effects.
23. CNS Spectrums, 2008 (PMID 18204410): A 2008 study explored the therapeutic possibility of Semax for depression.
24. Frontiers in Aging, 2026 (PMID 42021992): A 2026 review discussed therapeutic peptides in gerontology and noted the gap between regional regulatory approval and global acceptance.
25. Journal of the American Academy of Orthopaedic Surgeons, 2026 (PMID 41490200): A 2026 review examined therapeutic peptides in orthopedics and called out the challenges of translating preclinical promise into FDA-approved products.
26. Neuropeptides, 2025 (PMID 41004910): A 2025 review examined the modulation of neuropathological pathways by bioactive peptides and noted the difficulty of assessing evidence quality when most studies originate from a single country.
27. Acta Naturae, 2025 (PMID 41479572): A 2025 study explored the potential of Semax and its derivative for correcting pathological impairments in an animal model of Alzheimer's disease.
28. Journal of Inorganic Biochemistry, 2016 (PMID 27586814): A 2016 study examined the influence of N-terminus acetylation of Semax on copper(II) and zinc(II) coordination and biological properties.
29. ACS Chemical Neuroscience, 2022 (PMID 35080861): A 2022 study found that Semax affects copper-induced Aβ aggregation and amyloid formation in artificial membrane models.
30. Rossiiskii Fiziologicheskii Zhurnal, 2010 (PMID 21268834): A 2010 study examined nootropic and analgesic effects of Semax following different routes of administration.